Latham & Watkins Represents Zevra Therapeutics in Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a commercial-stage company focused on providing therapies for people living with rare disease, has announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of US$150 million upon the closing of the transaction, which is expected to take place within 30 to 45 days, subject to customary closing conditions.

Latham & Watkins LLP represents Zevra in the transaction with a corporate team led by partners Andrew Clark and Nathan Ajiashvili, with associate Eirene Kim. Advice was also provided on regulatory matters by partner Elizabeth Richards and counsel Monica Groat; on tax matters by partner Pardis Zomorodi; and on public company representation matters by partner Jenna Cooper, with associate Naseem Faqihi Alawadhi.